Please login to the form below

Not currently logged in

Marc Becker joins CRISPR Therapeutics

He becomes chief financial officer

CRISPR Therapeutics Marc BeckerCRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.

Becker brings over 20 years of commercial, operational and corporate finance expertise to the role, having held senior positions at BankBoston, Genzyme, KPMG and rEVO Biologics.

He joins the Switzerland-headquartered biopharmaceutical company from rEVO Biologics, where he served as its chief financial officer from 2012 until February this year.

While at rEVO, Becker was responsible for leading the finance department, directing the firm's market strategy and managing its governance.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Marc's extensive network and proven track record to establish internal controls will be vital as we continue to engage in key strategic ventures to support the discovery, development and commercialisation of new breakthrough therapeutics.”

Becker said: “I am excited to join the CRISPR Therapeutics leadership team as the company's growth accelerates with the introduction of strategic partnerships and ventures.

“Our technology is truly revolutionary and I'm delighted to be part of the team that will enable the development of life-changing medicines.”

21st March 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...